Rituximab treatment in resistant lupus nephritis: A single-center prospective study

Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE) and failure to respond to traditional immunosuppression increases morbidity and mortality. Rituximab has been considered a novel therapeutic option for the management of SLE. Materials and methods: We conducted a single -center, prospective, observational study from July 2018 to June 2019 to evaluate the effectiveness of rituximab in patients with resistant LN. Resistant LN was defined as the failure to respond to conventional immunosuppressive therapy including both cyclophosphamide and mycophenolate mofetil. All adult patients (> 18 years) with biopsy -proven class III/IV LN were included in the study. Four doses of intravenous rituximab (375 mg/m(2)) on 0, 1, 2, 3 weeks were administered. Patients were followed for 6 months, and the rates of complete renal response (CRR), partial renal response (PRR), or no renal response (NRR) were measured. The change in baseline 24 -hour urine protein, mean serum creatinine levels, and mean serum CD -19 levels at 24 weeks were also measured. Results: Six months after rituximab therapy, total sustained renal response (CRR+PRR) was observed in 52% cases of resistant LN (CRR was achieved in 24% of patients and PRR in 28%, respectively). Rituximab was associated with a significant decline in the 24 -hour urine protein, even in non -responders. However, the improvement in eGFR and serum creatinine was not statistically significant. The mean absolute CD -19 count was significantly low in responders compared to the non -responder group. Conclusion: Rituximab is a safe and effective therapeutic strategy for patients with resistant LN.